Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione

1. A solid form of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione, characterized by an X-ray powder diffraction pattern comprising a peak at 5.5 degrees±0.2 degrees 2-theta, on the 2-theta scale with lambda=1.54 angstroms (Cu Kα).

2. The solid form of claim 1 , characterized by an X-ray powder diffraction pattern as shown in FIG. 1 .

3. The solid form of claim 1 , characterized by an X-ray powder diffraction pattern comprising peaks at 20.4, 22.1, and 24.7 degrees±0.2 degrees 2-theta, on the 2-theta scale with lambda=1.54 angstroms (Cu Kα).

4. The solid form of claim 1 , characterized by an X-ray powder diffraction pattern comprising peaks at 17.7, 18.4, 18.9, and 20.8 degrees±0.2 degree 2-theta, on the 2-theta scale with lambda=1.54 angstroms (Cu Kα).

5. The solid form of claim 1 , characterized by an X-ray powder diffraction pattern comprising peaks at 5.5, 9.4, 11.8, 13.4, 15.3, 24.7, and 29.3 degrees±0.2 degree 2-theta, on the 2-theta scale with lambda=1.54 angstroms (Cu Kα).

6. The solid form of claim 1 , characterized by an X-ray powder diffraction pattern comprising peaks at three or more of 5.5, 9.4, 11.8, 13.4, 15.3, 17.7, 18.4, 18.9, 20.4, 20.8, 22.1, 24.7, and 29.3, degrees±0.2 degrees 2-theta, on the 2-theta scale with lambda=1.54 angstroms (Cu Kα).

7. The solid form of claim 1 , characterized by a differential scanning calorimetry (DSC) thermogram as shown in FIG. 2 when heated at a rate of 10° C./min.

8. The solid form of claim 1 , characterized by a differential scanning calorimetry (DSC) thermogram comprising an endothermic peak at about 228° C. when heated at a rate of 10° C./min.

9. The solid form of claim 1 , characterized by a thermogravimetric analysis profile as shown in FIG. 3 when heated at a rate of 10° C./min.

10. The solid form of claim 1 , characterized by a dynamic vapor sorption (DVS) profile as shown in FIG. 4 .

11. A process for preparing the solid form of claim 1 , comprising (i) dissolving 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione in a solvent to form a solution; and (ii) concentrating the solution.

12. The process of claim 11 , wherein the solvent comprises

a mixture of ethyl acetate/dichloromethane/petroleum ether in a ratio of volumes of about 1:1:5; ethyl acetate;

a mixture of 2-propanol/ethyl acetate in a ratio of volumes of about 1:1;

a mixture of 2-methyl-1-propanol/ethyl acetate in a ratio of volumes of about 1:1; a

mixture of 1-butanol/ethyl acetate in a ratio of volumes of about 1:1;

a mixture of 3-methylbutanol/tetrahydrofuran (THF) in a ratio of volumes of about 1:1; a

mixture of 3-methylbutanol/ethyl acetate in a ratio of volumes of about 1:1;

a mixture of THF/water in a ratio of volumes of about 1:1;

a mixture of acetonitrile/water in a ratio of volumes of about 1:1;

a mixture of methyl t-butyl ether (MTBE)/ethyl acetate in a ratio of volumes of about 1:1; or

a mixture of water/ethyl acetate in a ratio of volumes of about 1:1.

13. A pharmaceutical composition comprising the solid form of claim 1 and a pharmaceutically acceptable excipient.

14. The pharmaceutical composition of claim 13 , further comprising a solid form of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione which is amorphous.

15. A method of treating cancer in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the solid form of claim 1 .

16. The method of claim 15 , wherein the cancer is brain, lung, breast, ovarian, bladder, neuroblastoma, renal, or pancreatic cancer.

17. A method of treating traumatic brain injury in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the solid form of claim 1 .